The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based … (NCT06717295) | Clinical Trial Compass
RecruitingNot Applicable
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
Argentina, Nigeria, United Kingdom6,000 participantsStarted 2025-12-20
Plain-language summary
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. By analysing blood samples using artificial intelligence, the study seeks to create a safe, non-invasive method to enhance cancer diagnosis and monitor treatment responses over time.
Who can participate
Age range
40 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Phase 1 (Common Cancer Early Detection - CCANED)
Inclusion Criteria:
* Age: Adults aged 40 years or older.
* Confirmed diagnosis of one of the following common cancers: Non-Small Cell Lung Cancer (NSCLC), Glioblastoma Multiforme (GBM), Colorectal Cancer, Hepatocellular Carcinoma (HCC), Breast Cancer, Prostate Cancer, Ovarian Cancer, Pancreatic Cancer.
Exclusion Criteria:
* Currently pregnant.
* Presence of any active infectious diseases.
* Use of anticoagulant or antiplatelet drugs within the past 2 weeks.
* Any medical or psychological conditions that may affect the participant's ability to comply with study procedures.
Phase 2 ( Cancer Immuno-Profiling of Hematologic and Extracellular RNA - CIPHER)
Inclusion Criteria:
* Adults aged 40 years or older.
* Confirmed diagnosis of: Hepatocellular Carcinoma (HCC), Non-Small Cell Lung Cancer (NSCLC)
* Willingness to provide blood samples at the specified intervals (baseline, 6 weeks, and 6 months post-therapy initiation).
Exclusion Criteria:
* Presence of another malignancy unless it has been in remission for at least 5 years.
* Significant uncontrolled co-morbid conditions that may interfere with study participation or outcomes.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Identification of Platelet RNA Biomarkers Distinguishing Cancer Patients from Controls
Timeframe: Baseline (single time point)
2
Identification of RNA Biomarkers Correlating with Therapeutic Response (Phase 2)
Timeframe: Baseline to 6 months post-therapy initiation
3
Association Between Immune Cell Transcriptomes and AI-Based Platelet Signals
Timeframe: Baseline to 6 months post-therapy initiation